William Blair Issues Optimistic Outlook for APLS Earnings

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) – Analysts at William Blair upped their Q3 2025 earnings per share (EPS) estimates for shares of Apellis Pharmaceuticals in a research note issued on Tuesday, April 1st. William Blair analyst L. Hanbury-Brown now expects that the company will post earnings of ($0.15) per share for the quarter, up from their prior forecast of ($0.17). The consensus estimate for Apellis Pharmaceuticals’ current full-year earnings is ($1.70) per share. William Blair also issued estimates for Apellis Pharmaceuticals’ Q4 2025 earnings at ($0.07) EPS, FY2025 earnings at ($0.73) EPS and Q1 2026 earnings at $0.02 EPS.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its earnings results on Friday, February 28th. The company reported ($0.29) earnings per share for the quarter, topping the consensus estimate of ($0.37) by $0.08. The firm had revenue of $212.50 million during the quarter, compared to analysts’ expectations of $197.92 million. Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The firm’s revenue was up 45.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.73) earnings per share.

Other equities research analysts have also issued reports about the stock. Wedbush cut their price target on shares of Apellis Pharmaceuticals from $30.00 to $29.00 and set a “neutral” rating on the stock in a research note on Monday, March 3rd. JPMorgan Chase & Co. lifted their target price on Apellis Pharmaceuticals from $50.00 to $54.00 and gave the stock an “overweight” rating in a research report on Tuesday, March 4th. The Goldman Sachs Group decreased their target price on Apellis Pharmaceuticals from $36.00 to $32.00 and set a “neutral” rating for the company in a research report on Monday, March 3rd. Scotiabank lifted their price target on Apellis Pharmaceuticals from $30.00 to $31.00 and gave the stock a “sector perform” rating in a research report on Wednesday. Finally, HC Wainwright reissued a “buy” rating and issued a $57.00 price objective on shares of Apellis Pharmaceuticals in a report on Monday, March 3rd. Eight equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Apellis Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $45.59.

Apellis Pharmaceuticals Stock Down 11.3 %

Shares of NASDAQ:APLS opened at $19.97 on Friday. The firm has a 50 day simple moving average of $26.22 and a 200-day simple moving average of $29.05. Apellis Pharmaceuticals has a twelve month low of $19.76 and a twelve month high of $57.85. The company has a current ratio of 4.36, a quick ratio of 3.73 and a debt-to-equity ratio of 1.91. The company has a market capitalization of $2.51 billion, a PE ratio of -9.84 and a beta of 0.85.

Hedge Funds Weigh In On Apellis Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the stock. Charles Schwab Investment Management Inc. boosted its holdings in Apellis Pharmaceuticals by 1.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 956,362 shares of the company’s stock worth $27,581,000 after buying an additional 9,328 shares in the last quarter. Cerity Partners LLC boosted its stake in shares of Apellis Pharmaceuticals by 311.2% during the 3rd quarter. Cerity Partners LLC now owns 31,381 shares of the company’s stock worth $905,000 after acquiring an additional 23,749 shares in the last quarter. Sphera Funds Management LTD. acquired a new stake in shares of Apellis Pharmaceuticals in the 3rd quarter worth approximately $6,226,000. XTX Topco Ltd acquired a new stake in shares of Apellis Pharmaceuticals in the 3rd quarter worth approximately $206,000. Finally, Barclays PLC increased its stake in Apellis Pharmaceuticals by 18.0% in the 3rd quarter. Barclays PLC now owns 255,897 shares of the company’s stock valued at $7,381,000 after purchasing an additional 39,019 shares in the last quarter. 96.29% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Apellis Pharmaceuticals

In other news, insider Caroline Baumal sold 2,816 shares of the stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $33.81, for a total transaction of $95,208.96. Following the completion of the transaction, the insider now directly owns 55,560 shares of the company’s stock, valued at approximately $1,878,483.60. This represents a 4.82 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Timothy Eugene Sullivan sold 2,170 shares of the firm’s stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $28.70, for a total value of $62,279.00. Following the completion of the sale, the chief financial officer now directly owns 88,100 shares of the company’s stock, valued at $2,528,470. This represents a 2.40 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 66,054 shares of company stock worth $1,952,719 over the last ninety days. 6.80% of the stock is currently owned by company insiders.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).